|Trade names||Signifor, Signifor LAR|
|Subcutaneous injection, intramuscular injection|
|Chemical and physical data|
|Molar mass||1047.227 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States and the European Union for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.
The most common side effects include hyperglycaemia (high blood sugar levels), diabetes, diarrhoea, abdominal pain (stomach ache), nausea (feeling sick), cholelithiasis (gallstones), injection site reactions, and tiredness.
- "Drug Approval Package: Signifor (pasireotide) Injection NDA #200677". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 13 May 2020.
- "Signifor EPAR". European Medicines Agency (EMA). Retrieved 13 May 2020. This article incorporates text from this source, which is in the public domain.
- "Summary of Product Characteristics: Signifor" (PDF). European Medicines Agency.
- "Pasireotide Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 13 May 2020.
- "EU/3/09/671". European Medicines Agency. 17 September 2018. Retrieved 13 May 2020. This article incorporates text from this source, which is in the public domain.
- Mancini T, Porcelli T, Giustina A (October 2010). "Treatment of Cushing disease: overview and recent findings". Therapeutics and Clinical Risk Management. 6: 505–16. doi:10.2147/TCRM.S12952. PMC 2963160. PMID 21063461.
- "Signifor- pasireotide injection". DailyMed. 15 January 2020. Retrieved 13 May 2020.
- "Signifor LAR- pasireotide kit". DailyMed. 17 December 2019. Retrieved 13 May 2020.
- EMEA Approval for Pasireotide
- "FDA Approves Pasireotide for Cushing's Disease".
- "Signifor LAR (pasireotide) for injectable suspension". U.S. Food and Drug Administration (FDA). 1 March 2016. Retrieved 13 May 2020.
- Tucker ME (17 December 2014). "FDA Approves Pasireotide for Treating Acromegaly". Medscape. Retrieved 2 August 2015.
- "Pasireotide". Drug Information Portal. U.S. National Library of Medicine.
|This hormonal preparation article is a stub. You can help Wikipedia by expanding it.|